✓ VerifiedFDA pharmacology/toxicology review, p. 22Source ↗
Carcinogenicity
Not conducted; published mouse thymus-transplant literature reviewed
“No carcinogenicity/tumorigenicity studies were conducted.”
✓ VerifiedFDA pharmacology/toxicology review, p. 22Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not applicable: cells not genetically modified
“No in vitro or in vivo genotoxicity, carcinogenicity, or developmental and reproductive toxicity (DART) studies were conducted with RVT-802.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Not conducted; published thymectomy literature suggests minimal risk
“No DART studies were conducted.”
✓ VerifiedFDA pharmacology/toxicology review, p. 21Source ↗
Safety pharmacology
Not conducted
“No safety pharmacology studies were conducted.”
✓ VerifiedFDA pharmacology/toxicology review, p. 21Source ↗
Genotox: Ames
Not conducted
“No in vitro or in vivo genotoxicity, carcinogenicity, or developmental and reproductive toxicity (DART) studies were conducted with RVT-802.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Genotox: in vitro mammalian
Not conducted
“No in vitro or in vivo genotoxicity, carcinogenicity, or developmental and reproductive toxicity (DART) studies were conducted with RVT-802.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Genotox: in vivo
Not conducted
“No in vitro or in vivo genotoxicity, carcinogenicity, or developmental and reproductive toxicity (DART) studies were conducted with RVT-802.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Carcinogenicity model
Not conducted; literature on thymus transplantation in tumor-bearing mice reviewed; risk considered minimal
“Although the thymus products administered were not identical to RVT-802 and the studies were conducted in tumor-bearing mice (which does not reflect the clinical scenario), these data combined with the existing clinical safety data for RVT-802, indicate that the risk of carcinogenicity after RVT-802 transplantation in humans appears to be minimal.”
✓ VerifiedFDA pharmacology/toxicology review, p. 22Source ↗
Carcinogenicity timing
Not required: carcinogenicity studies not conducted and not indicated
“In vitro or in vivo genotoxicity, carcinogenicity, or developmental and reproductive toxicity studies were not conducted with RETHYMIC, nor were they indicated.”
✓ VerifiedFDA summary basis for approval, p. 12Source ↗
hERG / QT
Not conducted (no safety pharmacology studies)
“No safety pharmacology studies were conducted.”
✓ VerifiedFDA pharmacology/toxicology review, p. 21Source ↗